Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00865215 · ClinicalTrials.gov registry record · Phase 1
A Relative Bioavailability Study of Propranolol Hydrochloride 160 mg Tablets Under Fasting Conditions
A Phase 1 study, sponsored by Actavis.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT00865215: Completed Phase 1 study, sponsored by Actavis.
NCT00865215 is a Phase 1 study that has completed, run by Actavis. The registered enrollment target is 60 participants, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00865215, a Phase 1 study, has completed, sponsored by Actavis.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
The purpose of this study is TO compare the relative bioavailability of Propranolol Hydrochloride Extended Release Capsules 160 mg (Actavis) with that of INDERAL® LA 160 mg Capsules (Wyeth Pharmaceuticals) following a single oral dose (1 x 160 mg) in healthy adult volunteers under fasting conditions.
Interventions
- DRUG Propranolol Hydrochloride Extended Release Capsules 160 mg
- DRUG INDERAL® LA 160 mg Capsules, single dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2005-04 |
| Est. Completion | 2005-04 |
| Phase | Phase 1 |
What the finished NCT00865215 record still lists
NCT00865215 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which Propranolol Hydrochloride Extended Release Capsules 160 mg is the first listed.
NCT00865215 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00865215 about?
NCT00865215 is a clinical study titled "A Relative Bioavailability Study of Propranolol Hydrochloride 160 mg Tablets Under Fasting Conditions". The purpose of this study is TO compare the relative bioavailability of Propranolol Hydrochloride Extended Release Capsules 160 mg (Actavis) with that of INDERAL® LA 160 mg Capsules (Wyeth Pharmaceuticals) following a single oral dose (1 x 160 mg) in healthy adult volunteers under fasting conditions...
What is the current status of trial NCT00865215?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2005-04. Estimated completion is 2005-04.
What interventions are being tested in trial NCT00865215?
The interventions under investigation include: Propranolol Hydrochloride Extended Release Capsules 160 mg (DRUG), INDERAL® LA 160 mg Capsules, single dose (DRUG).
Who is sponsoring clinical trial NCT00865215?
This trial is sponsored by Actavis, which has 79 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00865215's enrollment target sits among peer trials
60 831st of 2000 higher than 1,106 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia